Condition: Depressive Disorder, Major · Anxiety Disorder · Sponsor: Mclean Hospital
The study will investigate whether a nociceptin receptor antagonist will normalize neural and behavioral processes of approach/avoidance decision-making in unmedicated individuals with major depressive disorder (MDD) and anxiety disorders. More specifically, the study aims to investigate dysregulation within (1) corticostriatal-midbrain circuitry and (2) nociceptin/orphanin FQ peptide and the nociceptin receptor (NOPR).
This description comes directly from the study's public registry record.
Ethan M Zhang, BA · 617-855-4434 · ezhang24@mclean.harvard.edu
David Crowley, ALM · 617-855-4432 · djcrowley@mclean.harvard.edu
Always discuss trial participation with your own doctor first.
| Mclean Hospital | Belmont, Massachusetts, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05232032